Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis

Authors

  • Marloes E. van Muijen Department of Dermatology, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands. Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands.
  • Sarah E. Thomas
  • Douwe Vellinga
  • Silke Bouwman
  • Martijn B.A. van Doorn
  • Klaziena Politiek
  • Marisol E. Otero
  • Juul M.P.A. van den Reek
  • Elke M.G.J. de Jong

DOI:

https://doi.org/10.2340/actadv.v102.685

Keywords:

Psoriasis, Biologics, Drug Survival, Guselkumab, Effectiveness, Safety

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol 2020; 82: 936-945.

https://doi.org/10.1016/j.jaad.2019.11.040

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol 2019; 180: 1039-1049.

https://doi.org/10.1111/bjd.17454

Mason KJ, Barker J, Smith CH, Hampton PJ, Lunt M, McElhone K, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol 2018; 154: 581-588.

https://doi.org/10.1001/jamadermatol.2018.0183

Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep 2018; 8: 16068.

https://doi.org/10.1038/s41598-018-34293-y

Schwensen JFB, Nielsen VW, Nissen CV, Sand C, Gniadecki R, Thomsen SF. Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real-world evidence study. J Eur Acad Dermatol Venereol 2021; 35: e341-e343.

https://doi.org/10.1111/jdv.17092

Iznardo H, Vilarrasa E, López-Ferrer A, Puig L. Real world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. Br J Dermatol 2021; 185: 660-662.

https://doi.org/10.1111/bjd.20416

Lee EB, Reynolds KA, Pithadia DJ, Egeberg A, Wu JJ. Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. J Dermatolog Treat 2020; 31: 342-343.

https://doi.org/10.1080/09546634.2019.1605133

Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, et al. Efficacy, safety and drug survival of IL-23, IL-17 and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat 2022; 33: 2352-2357.

https://doi.org/10.1080/09546634.2021.1961998

Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther 2021; 34: e14798.

https://doi.org/10.1111/dth.14798

Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol 2021; 22: 567-579.

https://doi.org/10.1007/s40257-021-00598-4

Lytvyn Y, Zaaroura H, Mufti A, AlAbdulrazzaq S, Yeung J. Drug survival of guselkumab in patients with plaque psoriasis: a 2 year retrospective, multicenter study. JAAD Int 2021; 4: 49-51.

https://doi.org/10.1016/j.jdin.2021.05.003

van der Schoot LS, van den Reek J, Grine L, Schots L, Kievit W, Lambert JLW, et al. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study. Trials 2021; 22: 707.

https://doi.org/10.1186/s13063-021-05681-z

Eyerich K, Weisenseel P, Pinter A, Schäkel K, Asadullah K, Wegner S, et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open 2021; 11: e049822.

https://doi.org/10.1136/bmjopen-2021-049822

Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2019; 181: 450-458.

https://doi.org/10.1111/bjd.17738

Enos CW, Ramos VL, McLean RR, Lin TC, Foster N, Dube B, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol 2022; 86: 68-76.

https://doi.org/10.1016/j.jaad.2021.06.883

Downloads

Published

2022-08-11

How to Cite

van Muijen, M. E., Thomas, S. E., Vellinga, D., Bouwman, S., van Doorn, M. B., Politiek, K., Otero, M. E., van den Reek, J. M., & de Jong, E. M. (2022). Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis. Acta Dermato-Venereologica, 102, adv00755. https://doi.org/10.2340/actadv.v102.685

Issue

Section

Short Communication

Categories